Details for Patent: 5,798,368

Title:	Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNF.alpha. levels
Abstract:	Tetrasubstituted 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNF.alpha. in a mammal. A typical embodiment is 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline.
Inventor(s):	Muller; George W. (Bridgewater, NJ), Stirling; David I. (Branchburg, NJ), Chen; Roger Shen-Chu (Edison, NJ)
Assignee:	Celgene Corporation (Warren, NJ)
Filing Date:	Aug 22, 1996
Application Number:	08/701,494
Claims:	1. A compound of the formula: ##STR6## in which each of R.sup.1, R.sup.2, R.sup.3, and R.sup.4, independently of the others, is halo, alkyl of 1 to 4 carbon atoms, or alkoxy of 1 to 4 carbon atoms. 2. The compound according to claim 1 in which R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are the same and each is chloro, fluoro, methyl, or methoxy. 3. The compound according to claim 2 which is 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline. 4. The compound according to claim 2 which is 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4,5,6,7-tetrachloroisoindoline. 5. The compound according to claim 2 which is 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4,5,6,7-tetramethylisoindoline. 6. The compound according to claim 2 which is 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4,5,6,7-tetramethoxyisoindoline. 7. The method of reducing undesirable levels of TNF.alpha. in a mammal which comprises administering thereto an effective amount of a compound according to claim 1. 8. A pharmaceutical composition comprising a quantity of a compound according to claim 1 sufficient upon administration in a single or multiple dose regimen to reduce levels of TNF.alpha. in a mammal in combination with a carrier.